Alcon (ALC) Gets a Buy from RBC Capital
RBC Capital analyst Jack Reynolds-Clark maintained a Buy rating on Alcon yesterday and set a price target of CHF80.00.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
According to TipRanks, Reynolds-Clark is a 2-star analyst with an average return of 0.3% and a 37.50% success rate. Reynolds-Clark covers the Healthcare sector, focusing on stocks such as Alcon, ConvaTec, and Smith & Nephew.
In addition to RBC Capital, Alcon also received a Buy from Needham’s David Saxon in a report issued yesterday. However, on the same day, Barclays reiterated a Hold rating on Alcon (NYSE: ALC).
Based on Alcon’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of CHF2.74 billion and a net profit of CHF218.77 million. In comparison, last year the company earned a revenue of CHF2.5 billion and had a net profit of CHF284 million
Read More on ALC:
Disclaimer & DisclosureReport an Issue
- Alcon price target lowered to $70 from $82 at Stifel
- Alcon Q1 2026 Sales Rise 10% as New Eye-Care Products Power Growth and $1.5 Billion Buyback
- Analyst Reiterates Sell on Execution and Valuation Risks, Trims Price Target to CHF 55 Amid Competitive Pressures
- Alcon price target lowered to $87 from $92 at BTIG
- William Blair med tech analyst holds an analyst/industry conference call
